STIM at a glance
Neuronetics, Inc. (STIM, SEC CIK 1227636) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Neuronetics, Inc. (STIM) reported revenue of $149.2 million (up 99.2% from FY2024) and a net loss of $39.0 million. Diluted EPS was -$0.59.
- As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding Neuronetics, Inc. (STIM) shares worth $13.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Chernett Jorey on November 13, 2026 of 2,187,051 shares at $1.15 per share.
- In the last 90 days, STIM insiders reported 2 open-market purchases ($120K) and 5 open-market sales ($4.5M) on Form 4, a net sale of $4.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $149.2M
- +99.2% vs prior year
- Insiders · 90 days
- 2 buys · 5 sells
- Net −$4.4M
- 13F holders
- 20 funds
- $13.2M · +2 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 1.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development and commercialization of NeuroStar Advanced Therapy System, a non-invasive TMS treatment for MDD and OCD, plus operation of Greenbrook mental health treatment centers
- New emphasis on fully integrated care via Greenbrook acquisition, adding 93 clinics and SPRAVATO treatment for treatment-resistant depression
- Strategic shift to vertically integrated provider of mental health solutions combining product and service, aiming for market consolidation and expanded patient access
- Revenue $149.2M in 2025, up 99% YoY; increased U.S. clinic revenues to 59% from 6% prior year due to Greenbrook acquisition; 658 employees as of December 2025
- Noteworthy Greenbrook restructuring closing dozens of underperforming clinics and focus on Regional Account Managers to build referral pathways
Risk Factors
- Cybersecurity risk oversight by board Audit Committee with quarterly enterprise risk profile reports from Head of IT
- Head of IT with 20+ years experience leads cybersecurity program and partners with third-party experts for risk identification
- Regular assessment using industry-standard KPIs for prevention, detection, mitigation, and remediation of cybersecurity incidents
Management Discussion & Analysis
- Revenue $149.2M in 2025, up 99% YoY from $74.9M in 2024; U.S. revenue $146.0M up 101% YoY; international $3.1M up 29% YoY
- Gross margin 48.5% in 2025 vs 72.3% in 2024, decline due to Greenbrook clinic business inclusion and reduced treatment session revenue
- Best performing segment: Clinic revenue $87.0M (59% of US revenues) in 2025 vs $4.4M (6%) in 2024; Worst: NeuroStar System revenue $14.3M (10%) in 2025 vs $15.3M (21%) in 2024
- Operating loss improved to $(31.4)M from $(34.6)M; net loss $(39.1)M vs $(43.7)M; cash $28.1M with operating cash flow negative $20.4M; $70M debt outstanding; raised $26.8M net via equity offerings and ATM
- Management expects clinic revenue growth in 2026; anticipates decreased sales/marketing expense but increased general/administrative expense; key risks include financing availability and regulatory challenges
AI summary of the STIM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes identified from the March 17, 2026 Form 10-K and May 5, 2026 Form 10-Q
Management Discussion & Analysis
- Q3 revenue $42.0M, up 13% YoY from $37.3M
- Gross margin 52.2% vs 45.9% YoY, net loss $1.6M vs $9.4M
- Best segment Greenbrook revenue $26.2M, up 20%; NeuroStar $15.8M, up $0.3M
- Cash $22.1M vs $28.1M at December 31; nine-month operating cash outflow $9.2M
- March 31, 2027 revenue covenant risk, substantial doubt about going concern despite lender discussions
AI summary of the STIM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- $30.0M gross equity offering: 18.75M shares at $1.60 each, creating substantial dilution risk
- Underwriters hold a 30-day option for 2.8125M additional shares, potentially increasing proceeds and dilution
Item 8.01: Other Events
- Neuronetics launched an offering on November 10, 2026, signaling planned external financing
- Offering pricing announced the same day, with terms and proceeds detailed in Exhibit 99.2
Item EX-99.1: Item EX-99.1
- Proposed underwritten common-stock offering, with Neuronetics selling all shares and underwriters holding a 15% overallotment option
- Offering size, price and timing remain undetermined, creating potential shareholder dilution once finalized
Item EX-99.2: Item EX-99.2
- $30 million equity offering priced at $1.60 per share, creating substantial dilution for existing shareholders
- 18,750,000 shares offered, with underwriters’ 30-day option for 2,812,500 additional shares
Item 1.01: Entry into a Material Definitive Agreement
- $30.0 million gross equity offering: 18.75 million shares at $1.60 each
- Underwriters’ 2.8125 million-share option could raise additional $4.5 million gross
Item 8.01: Other Events
- Neuronetics launched and priced a capital offering on November 10, 2026
- Offering proceeds expected to support liquidity and corporate needs, with terms in Exhibits 99.1 and 99.2
Item 1.01: Entry into a Material Definitive Agreement
- Amendment modifies certain revenue covenants under Neuronetics’ existing Perceptive credit facility
- Covenant relief conditional on optional prepayment of at least $15,000,000
AI summaries of STIM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for STIM
Don't miss the next STIM filing
- Alerts as it files. A push when STIM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut STIM, by share count.
- Ask anything. An AI agent that reads every STIM filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MUIR GLENN P | A | Nov 16, 2026 | 175,000 | $1.31 |
| MUIR GLENN P | A | Nov 16, 2026 | 175,000 | $1.31 |
| Chernett Jorey | Sell | Nov 13, 2026 | 2,187,051 | $1.15 |
| Cucuz Sasha | A | Nov 13, 2026 | 370,370 | $1.35 |
| Cucuz Sasha | J | Nov 12, 2026 | 625,000 | $1.60 |
| Chernett Jorey | Sell | Nov 12, 2026 | 706,840 | $1.43 |
| CASCELLA ROBERT | A | Nov 12, 2026 | 128,242 | $1.50 |
| CASCELLA ROBERT | A | Nov 12, 2026 | 44,758 | $1.56 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $74.9M | $149.2M |
| Gross Profit | $51.7M | $54.2M | $72.3M |
| Operating Income | - | -$34.6M | -$31.4M |
| Net Income | -$30.2M | -$43.7M | -$39.0M |
| Gross Margin | - | 72.3% | 48.5% |
| Op. Margin | - | -46.2% | -21.1% |
| Net Margin | - | -58.4% | -26.1% |
| Balance Sheet | |||
| Total Assets | - | $140.9M | $141.6M |
| Equity | $34.2M | $27.7M | $22.4M |
| ROE | -88.3% | -157.8% | -174.3% |
| Per Share | |||
| EPS | $-1.05 | $-1.38 | $-0.59 |
| Cash Flow | |||
| Operating CF | - | -$31.0M | -$20.4M |
Source: XBRL data in Neuronetics, Inc. (STIM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate STIM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 20 | $13.2M |
| Q2 2026 | 18 | $4.9M |
| Q1 2026 | 19 | $9.7M |
| Q4 2025 | 20 | $10.3M |
| Q3 2025 | 21 | $21.8M |
| Q2 2025 | 18 | $29.5M |
| Q1 2025 | 16 | $18.1M |
| Q4 2024 | 6 | $2.7M |
- Morgan Stanley+690.4K (+1098%)
- Citadel Advisors LLC+217.9K (+52%)
- Millennium Management+143.0K (+72%)
- Bank of America Corp+34.6K (+51%)
- Vanguard Capital Management LLC+20.3K (+1%)
- BlackRock−144.0K (-24%)
- AQR Capital Management−97.2K (-82%)
- Invesco Ltd−26.1K (-38%)
- Goldman Sachs Group−11.1K (-4%)
- Citigroup−306 (-12%)
- D.E. Shaw & Co+461.7K
- Renaissance Technologies LLC+424.4K
- BNY Mellon+176.3K
- Two Sigma Investments+13.9K
- StoneX Group Inc.−12.1K
- FMR LLC (Fidelity)−5.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 138 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
STIM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 2, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 4 | Aug 17, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Jul 23, 2026 | - | - | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 4 | Jul 15, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | May 29, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 29, 2026 | - | Analysis |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
STIM SEC filings: frequently asked questions
Are STIM insiders buying or selling?
In the last 90 days, Neuronetics, Inc. (STIM) officers, directors and 10% owners reported 2 open-market purchases worth $120,460 by 1 insider and 5 open-market sales worth $4.5 million by 1 insider on Form 4, a net sale of $4.4 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold STIM stock?
As of September 30, 2026, the largest Neuronetics, Inc. (STIM) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($3.6 million), Morgan Stanley ($1.8 million), Citadel Advisors LLC ($1.5 million), D.E. Shaw & Co ($1.1 million), BlackRock ($1.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was STIM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Neuronetics, Inc. (STIM) reported revenue of $149.2 million (up 99.2% from FY2024) and a net loss of $39.0 million. Diluted EPS was -$0.59. The figures come from the XBRL data in the 10-K.
What are the main risks in STIM's latest 10-K?
In the 10-K filed March 17, 2026, Neuronetics, Inc. (STIM) flagged: Cybersecurity risk oversight by board Audit Committee with quarterly enterprise risk profile reports from Head of IT. Head of IT with 20+ years experience leads cybersecurity program and partners with third-party experts for risk identification. (AI summary of the Risk Factors section.)
What did STIM report in its latest 8-K?
Neuronetics, Inc. (STIM) filed an 8-K on November 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 8.01 (Other Events). $30.0M gross equity offering: 18.75M shares at $1.60 each, creating substantial dilution risk.
What are the latest STIM SEC filings?
Neuronetics, Inc. (STIM) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 19, 2026.
What is STIM's SEC CIK number?
Neuronetics, Inc. (STIM)'s SEC Central Index Key (CIK) is 1227636. EDGAR lists every STIM filing under that number.
Ask anything about STIM
The research agent reads STIM's filings, financials, insider trades and 13F holders, then answers with sources.